More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.07B
EPS
-2.55
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
0.948215
Previous close
$35.05
Today's open
$34.71
Day's range
$33.87 - $34.84
52 week range
$21.86 - $45.42
show more
CEO
Eric Venker
Employees
315
Headquarters
Durham, NC
Exchange
Nasdaq Global Select
Shares outstanding
206947758
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Nov 11, 2026

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.5% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks Investment Research • Nov 11, 2026

What Immunovant (IMVT) Said on Its Q2 Earnings Call
Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt Gline cautioned that the LISRAYA results covered only about five weeks on the market and included a boost from pharmacy inventory.
MarketBeat • Nov 9, 2026

Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Seeking Alpha • Nov 9, 2026

Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).
Benzinga • Nov 9, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in Period 2 continued to increase, reaching 80.0% ACR50 and 52.5% ACR70 at Week 28 FDA discussions planned for later this year to determine the path forward regarding the registrational program for IMVT-1402 in D2T RA In light of the evolving Sjögren's disease (SjD) landscape and recent data in the field, we expect it is unlikely that we will advance IMVT-1402 further in SjD beyond the ongoing, fully enrolled Phase 2 trial All other clinical development timelines remain on track Roivant will host a live conference call and webcast at 8:00 a.m.
GlobeNewsWire • Nov 9, 2026

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.
GlobeNewsWire • Oct 21, 2026

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
PRNewsWire • Oct 12, 2026

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
Business Wire • Oct 11, 2026

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.
PRNewsWire • Sep 25, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Immunovant Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.